

# Lab Notebook 2024

Callum Malcolm

## Contents

<b>LN Repository</b>	<b>2</b>
Rack 1 . . . . .	2
<b>January 2024</b>	<b>4</b>
<b>January 2024</b>	<b>4</b>
<b>March 2024</b>	<b>4</b>
<b>Monday 24-03-2024</b>	<b>4</b>
MR - CD20 Flow EpiDrug Pretreatment . . . . .	4
Protocol . . . . .	4
Results . . . . .	4
<b>Tuesday 25-03-2024</b>	<b>4</b>
RTX EC50_250324 RBL2 - Seeding . . . . .	4
Plate seeding protocol: . . . . .	4
RBL2 RTX DP - Dose 1 . . . . .	5
Dosing Protocol . . . . .	5
Plate Layout . . . . .	6
RBL2 RTX DP - Sample Collection Baseline . . . . .	7
Collection Protocol . . . . .	7

# LN Repository

## Rack 1

- Location: Tank 2, Rack 1, Row H (Bottom)

Location	Cap ID	Description	Date
1	Grey	Empty - Marker	-
2	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
3	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
4	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
5	C4 DP2	Ramos RTX CDC C4-DP2	-
6	C5 DP2	Ramos RTX CDC C5-DP2	-
7	C1 DP2	Ramos RTX CDC C1-DP2	-
8	R3 DP2	Ramos RTX CDC R3-DP2	-
9	C6 DP2	Ramos RTX CDC C6-DP2	-
10	C3 DP2	Ramos RTX CDC C3-DP2	-
11	C2 DP2	Ramos RTX CDC C2-DP2	-
12	-	-	-
13	-	-	-
14	-	-	-
15	-	-	-
16	-	-	-
17	-	-	-
18	-	-	-
19	-	-	-
20	-	-	-
21	-	-	-
22	-	-	-
23	-	-	-
24	-	-	-
25	-	-	-
26	-	-	-
27	-	-	-
28	-	-	-
29	-	-	-
30	-	-	-
31	Ramos BC 1	Ramos Barcode Pool 1	12/06/2024
32	Ramos BC 1	Ramos Barcode Pool 1	04/01/2023
33	Ramos BC 1	Ramos Barcode Pool 1 *	16/07/2024
34	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
35	Ramos BC 3	Ramos Barcode Pool 3	04/06/2024
36	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
37	Ramos BC 5	Ramos BC Pool 5	12/06/2024
38	Ramos BC 5	Ramos Barcode Pool 5	04/16/2024
39	Ramos BC 6	Ramos Barcode Pool 6	04/16/2024
40	-	-	-
41	-	-	-
42	-	-	-
43	-	-	-
44	-	-	-
45	-	-	-
46	-	-	-
47	-	-	-

Location	Cap ID	Description	Date
48	-	-	-
49	-	-	-
50	-	-	-
51	RBL1	RBL1 PDX	31/07/2023
52	RBL1	RBL1 PDX	31/07/2024
53	RBL1 PDX	RBL1 PDX	31/07/2024
54	BLLW	BLLW PDX Pool	31/07/2024
55	BLLW	BLLW PDX Pool	31/07/2024
56	N4	N4 PDX pool	07/11/2023
57	N4	N4 PDX pool	07/11/2023
58	N2 BC	N2 Barcoded pool	11/05/2023
59	N2 BC 5	N2 barcode pool 5	29/04/2024
60	A20	A20 Cell Pool	13/10/2024
61	A20	A20 Stock	13/10/2024
62	-	-	-
63	-	-	-
64	-	-	-
65	-	-	-
66	-	-	-
67	-	-	-
68	-	-	-
69	-	-	-
70	-	-	-
71	-	-	-
72	-	-	-
73	-	-	-
74	-	-	-
75	-	-	-
76	-	-	-
77	-	-	-
78	-	-	-
79	-	-	-
80	-	-	-
81	-	-	-
82	-	-	-
83	-	-	-
84	-	-	-
85	-	-	-
86	-	-	-
87	-	-	-
88	-	-	-
89	-	-	-
90	-	-	-
91	NA	NA	NA
92	NA	NA	NA
93	NA	NA	NA
94	A20 ME	B-IP-724-1L	-
95	A20 ME	B-IP-723 NM	-
96	A20 ME	B-IP-723-2L	-
97	A20 ME	723-2R	-
98	A20 ME	723-1L	-
99	A20 ME	710 NM - A20 Mouse Experiment	-

Location	Cap ID	Description	Date
100	NA	NA	NA

**January 2024**

**January 2024**

**March 2024**

**Monday 24-03-2024**

**MR - CD20 Flow EpiDrug Pretreatment**

**Protocol**

1.  $1 \times 10^6$  cells from each treatment group were split into 3 wells of a 96-well plate
2. Plate spun at 300xg 5 min and supernatant discarded
3. Cells were resuspended in FACS Staining buffer
  - 1ul CD20 (BD Cat# 562873) per 250uL
  - 12 uL in 3000uL
4. Plate incubated in the dark for 20min at 4C
5. Plate spun at 300xg 5 min and supernatant discarded
6. Samples were resuspended in 400uL PBS and transferred to FACS tubes

**Results**

- No clear alteration of CD20 expression due to Epigenetic drug pretreatment

**Tuesday 25-03-2024**

**RTX EC50\_250324 RBL2 - Seeding**

- Seeded an EC50 experiment comparing the effects of RTX on Baseline RBL2 in the presence of 25% NHS
- Seeded 1 plates with the same RBL2 Baseline population
- Used Rixathon (Catalogue#: )

**Plate seeding protocol:**

1. Diluted cell suspension to seed 10000 cells/well in 50 $\mu$ L amounts

Plate	Cell Line	Cell Count	Required Cell total	Required Volume total	CS cells/mL	Stock Volume (uL)	Media Volume (mL)
Plate 1	RBL2	$5.65 \times 10^5$	$7.00 \times 10^5$	3.5	$1.61 \times 10^5$	1238.9	2.2611

2. Made RTX dilutions and added to respective wells in 25 $\mu$ L
  - [RTX stock] = 10.3 mg/mL
  - Drug volumes are added in triplicate
  - Drug volumes are being added constitute 1/4 of well volume:

- [RTX working] needs to be 4x [RTX well]
  - 6 wells per condition, 25 $\mu$ L per well ~ minimum of 150 $\mu$ L per condition needed (recommend 200 $\mu$ L)


Dilution ID	Well [RTX] ( $\mu$ g/mL)	RTX Source	Source Volume ( $\mu$ L)	Media Volume ( $\mu$ L)	Working Stock [RTX] ( $\mu$ g/mL)
RTX 1	20.0	Stock	4.6500000000000004	595.4	79.8
RTX 2	10.0	RTX 1	300	300.0	39.9
RTX 3	5.0	RTX 2	300	300.0	20.0
RTX 4	2.5	RTX 3	300	300.0	10.0
RTX 5	1.2	RTX 4	300	300.0	5.0
RTX 6	0.6	RTX 5	300	300.0	2.5
RTX 7	0.3	RTX 6	300	300.0	1.2
RTX 8	0.2	RTX 7	300	300.0	0.6
RTX 9	0.1	RTX 8	300	600.0	0.3
CNTR	0.0	-	-	1000.0	0.0

3. Added HIAS/NHS to indicated wells

- 25 $\mu$ L/well
- Final well volume = 25% Serum (HIAS/NHS)

4. Plate is incubated for 48 hrs at 37C

### EC50\_250324 CDC Test RBL2



### RBL2 RTX DP - Dose 1

- Began RTX CDC In Vitro dosing
- Seeded RBL2 into 2x 6 well plates


### Dosing Protocol

1. Count CS and dilute to 2x10<sup>5</sup> cells in 1 mL
  - If cell count is below either re-culture or add required CS amount, spin down, and resuspend in 1mL
2. Add 1mL of cell suspension containing 2x10<sup>5</sup> cells to respective wells of 6-well plate


3. Made RTX dilutions and added to respective Rx wells in 500 $\mu$ L
  - [RTX stock] = 10.3 mg/mL
  - Drug volumes are being added constitute 1/4 of well volume:
    - [RTX working] needs to be 4x [RTX well]
  - 6 wells per RTX dosing, 500 $\mu$ L per well ~ minimum of 3000 $\mu$ L per condition needed (recommend 3500 $\mu$ L)
  - 1.4 uL RTX stock in 3.5mL media
  - 500 $\mu$ L media added to Cx wells
4. Added NHS to all wells
  - 500 $\mu$ L/well
  - Final well volume = 25% Serum (NHS)
4. Plates incubated for 24 hrs at 37C

#### Plate Layout

### RBL2 RTX DP1 Control 250325



### RBL2 RTX DP1 RR-RBL2 250325



## **RBL2 RTX DP - Sample Collection Baseline**

### **Collection Protocol**

1.  $1 \times 10^6$  cells added to eppendorf tubes
2. Spun down @ max speed @ 4C
3. Supernatant removed
4. Pellets flash frozen
5. Pellets saved at -80C